Benzinga | Jul 17, 2020 07:02AM EDT

Applied Therapeutics To Present Data On AT-007 For Treatment Of Galactosemia At Galactosemia Foundation 2020 Virtual Conference



NEW YORK, July 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced presentations covering the AT-007 Galactosemia development program at the Galactosemia Foundation 2020 Virtual Conference, July 17-19. The Galactosemia Foundation Conference is a unique platform that brings together patients and families with Galactosemia alongside researchers and physicians.

"We are excited to share our development progress with the Galactosemia community," said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics. "Our long-term partnership with the Galactosemia Foundation, families and physicians is essential to bringing treatment to patients."

Oral Presentation Details

Title AT-007: Development of an Oral Treatment for Patients with Galactosemia

Presenter Shoshana Shendelman, PhD, Chief Executive Officer of Applied Therapeutics

Time: Saturday, July 18 10:00 -- 11:00 a.m. ET

Title ACTION-Galactosemia: Clinical Experience with Adult Galactosemia Patients and Path Forward

Presenter Riccardo Perfetti, M.D., Ph.D., Chief Medical Officer of Applied Therapeutics

Time: Saturday, July 18 4:15 -- 5:00 p.m. ET

Title ACTION-Galactosemia Kids: Pediatric Study of AT-007 in Children with Galactosemia

Presenter Shoshana Shendelman, PhD, Chief Executive Officer of Applied Therapeutics

Time: Saturday, July 18 5:30 -- 6:15 p.m. ET

Slides will be available on the presentations and publications section of the Applied Therapeutics website following the conference.